Drug Profile
Denagliptin
Alternative Names: 823093; GW 823093; GW823093C; RedonaLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihyperglycaemics; Aromatic amino acids; Pyrrolidines; Small molecules
- Mechanism of Action Dipeptidyl-peptidase and tripeptidyl-peptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 20 Apr 2015 GlaxoSmithKline withdraws a phase II/III trial in Type-2 diabetes mellitus in USA and Finland due to the cancellation of the trial (NCT00387972; EudraCT2006-002157-79)
- 08 Nov 2006 Suspended - Phase-III for Type-2 diabetes mellitus in United Kingdom (PO)
- 28 Jul 2006 Phase-II/III clinical trials in Type-2 diabetes mellitus in United Kingdom (PO)